Evidence map›Paper›PMID 41342084›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Sulphonamide derivatives with a triazine core as novel inducers of apoptosis and pyroptosis in glioblastoma multiforme cells.

Olga Klaudia Szewczyk-Roszczenko, Katarzyna Kotwica-Mojzych, Piotr Roszczenko, Mariusz Mojzych, Adolfo Rivero-Müller, Karolina Czapla, Alicja Przybyszewska-Podstawka, Krzysztof Bielawski, Robert Czarnomysy

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Olga Klaudia Szewczyk-RoszczenkoDepartment of Synthesis and Technology of Drugs, Medical University of Białystok, Białystok, Poland.ORCID 0000-0002-3719-6583
Katarzyna Kotwica-MojzychDepartment of Histology, Embriology and Cytophisiology, Medical University of Lublin, ul. Radziwiłłowska 11 (Collegium Medicum), Lublin, Poland.ORCID 0000-0002-3655-7324
Piotr RoszczenkoDepartment of Biotechnology, Medical University of Białystok, Białystok, Poland.ORCID 0000-0001-9180-5901
Mariusz MojzychCollegium Medicum, The Mazovian Academy in Plock, Płock, Poland.ORCID 0000-0002-9884-6068
Adolfo Rivero-MüllerDepartment of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Karolina CzaplaDepartment of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Alicja Przybyszewska-PodstawkaDepartment of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Krzysztof BielawskiDepartment of Synthesis and Technology of Drugs, Medical University of Białystok, Białystok, Poland.
Robert CzarnomysyDepartment of Synthesis and Technology of Drugs, Medical University of Białystok, Białystok, Poland.ORCID 0000-0002-7148-6111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive brain tumour with few effective treatment options. This study evaluated two novel triazine-based sulphonamides, MM118 and MM119, for their anticancer effects on GBM cells.

Indexed as

Antineoplastic AgentsApoptosisGlioblastomaPyroptosisSulfonamidesTriazinesAnimalsCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureNeoplasms, ExperimentalReactive Oxygen SpeciesAntineoplastic AgentsReactive Oxygen SpeciesSulfonamidesTriazinesapoptosisGlioblastoma multiformepyroptosistriazine sulphonamides

Identifiers

PMID41342084
PMCPMC12679848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.